Same Day Ex-vivo regional gene therapy: A novel strategy to enhance bone repair

Molecular Therapy

Volumn 19, Issue 5, 2011, Pages 960-968

  Virk, Mandeep S ^a   Sugiyama, Osamu ^a   Park, Sang H ^b   Gambhir, Sanjiv S ^c   Adams, Douglas J ^a   Drissi, Hicham ^a   Lieberman, Jay R ^a  

^a UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BONE MORPHOGENETIC PROTEIN 2; COMPLEMENTARY DNA; LENTIVIRUS VECTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE MARROW BUFFY COAT; BONE MARROW CELL; BONE REMODELING; CELL CULTURE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; EX VIVO GENE TRANSFER; FEMUR FRACTURE; FRACTURE HEALING; GENE OVEREXPRESSION; HISTOPATHOLOGY; IN VITRO STUDY; MALE; MICRO-COMPUTED TOMOGRAPHY; MORPHOMETRICS; NONHUMAN; OSSIFICATION; RAT; VIRAL GENE DELIVERY SYSTEM;

RATTUS;

EID: 79955582337     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2011.2     Document Type: Article

References (49)

1. Gamradt, SC and Lieberman, JR (2003). Bone graft for revision hip arthroplasty: biology and future applications. Clin Orthop Relat Res: 183-194. (Pubitemid 37499524)
2. St John TA, Vaccaro AR, Sah AP, Schaefer M, Berta SC, Albert T et al. (2003). Physical and monetary costs associated with autogenous bone graft harvesting. Am J Orthop (Belle Mead NJ) 32: 18-23.
3. Heneghan, HM and McCabe, JP (2009). Use of autologous bone graft in anterior cervical decompression: morbidity & quality of life analysis. BMC Musculoskelet Disord 10: 158.
4. Kim, DH, Rhim, R, Li, L, Martha, J, Swaim, BH, Banco, RJ et al. (2009). Prospective study of iliac crest bone graft harvest site pain and morbidity. Spine J 9: 886-892.
5. Govender, S, Csimma, C, Genant, HK, Valentin-Opran, A, Amit, Y, Arbel, R et al. (2002). Recombinant human bone morphogenetic protein-2 for treatment of open tibial fractures: a prospective, controlled, randomized study of four hundred and fifty patients. J Bone Joint Surg Am 84-A: 2123-2134. (Pubitemid 35417689)
6. Swiontkowski, MF, Aro, HT, Donell, S, Esterhai, JL, Goulet, J, Jones, A et al. (2006). Recombinant human bone morphogenetic protein-2 in open tibial fractures. A subgroup analysis of data combined from two prospective randomized studies. J Bone Joint Surg Am 88: 1258-1265. (Pubitemid 43837120)
7. Glassman, SD, Carreon, LY, Djurasovic, M, Campbell, MJ, Puno, RM, Johnson, JR et al. (2008). RhBMP-2 versus iliac crest bone graft for lumbar spine fusion: a randomized, controlled trial in patients over sixty years of age. Spine 33: 2843-2849.
8. Betz, OB, Betz, VM, Abdulazim, A, Penzkofer, R, Schmitt, B, Schröder, C et al. (2010) The repair of critical-sized bone defects using expedited, autologous BMP-2 geneactivated fat implants. Tissue Eng Part A 16: 1093-1101.
9. Vaidya, R, Carp, J, Sethi, A, Bartol, S, Craig, J and Les, CM (2007). Complications of anterior cervical discectomy and fusion using recombinant human bone morphogenetic protein-2. Eur Spine J 16: 1257-1265. (Pubitemid 350104617)
10. Crawford, CH 3rd, Carreon, LY, McGinnis, MD, Campbell, MJ and Glassman, SD (2009). Perioperative complications of recombinant human bone morphogenetic protein-2 on an absorbable collagen sponge versus iliac crest bone graft for posterior cervical arthrodesis. Spine 34: 1390-1394.
11. Haidar, ZS, Hamdy, RC and Tabrizian, M (2009). Delivery of recombinant bone morphogenetic proteins for bone regeneration and repair. Part A: Current challenges in BMP delivery. Biotechnol Lett 31: 1817-1824.
12. Shields, LB, Raque, GH, Glassman, SD, Campbell, M, Vitaz, T, Harpring, J et al. (2006). Adverse effects associated with high-dose recombinant human bone morphogenetic protein-2 use in anterior cervical spine fusion. Spine 31: 542-547.
13. Garrison, KR, Donell, S, Ryder, J, Shemilt, I, Mugford, M, Harvey, I et al. (2007). Clinical effectiveness and cost-effectiveness of bone morphogenetic proteins in the non-healing of fractures and spinal fusion: a systematic review. Health Technol Assess (Winchester, England) 11: 1-150, iii-iv.
14. Lieberman, JR, Daluiski, A, Stevenson, S, Wu, L, McAllister, P, Lee, YP et al. (1999). The effect of regional gene therapy with bone morphogenetic protein-2-producing bonemarrow cells on the repair of segmental femoral defects in rats. J Bone Joint Surg Am 81: 905-917. (Pubitemid 29354999)
15. Dragoo, JL, Lieberman, JR, Lee, RS, Deugarte, DA, Lee, Y, Zuk, PA et al. (2005). Tissueengineered bone from BMP-2-transduced stem cells derived from human fat. Plast Reconstr Surg 115: 1665-1673. (Pubitemid 40604737)
16. Lee, JY, Peng, H, Usas, A, Musgrave, D, Cummins, J, Pelinkovic, D et al. (2002). Enhancement of bone healing based on ex vivo gene therapy using human muscle-derived cells expressing bone morphogenetic protein 2. Hum Gene Ther 13: 1201-1211. (Pubitemid 34746700)
17. Rutherford, RB, Moalli, M, Franceschi, RT, Wang, D, Gu, K and Krebsbach, PH (2002). Bone morphogenetic protein-transduced human fibroblasts convert to osteoblasts and form bone in vivo. Tissue Eng 8: 441-452. (Pubitemid 34747801)
18. Carofino, BC and Lieberman, JR (2008). Gene therapy applications for fracturehealing. J Bone Joint Surg Am 90 Suppl 1: 99-110.
19. Gamradt, SC and Lieberman, JR (2004). Genetic modification of stem cells to enhance bone repair. Ann Biomed Eng 32: 136-147.
20. Feeley, BT, Conduah, AH, Sugiyama, O, Krenek, L, Chen, IS and Lieberman, JR (2006). In vivo molecular imaging of adenoviral versus lentiviral gene therapy in two bone formation models. J Orthop Res 24: 1709-1721. (Pubitemid 44203302)
21. Virk, MS, Conduah, A, Park, SH, Liu, N, Sugiyama, O, Cuomo, A et al. (2008). Influence of short-term adenoviral vector and prolonged lentiviral vector mediated bone morphogenetic protein-2 expression on the quality of bone repair in a rat femoral defect model. Bone 42: 921-931.
22. Li, G, Corsi-Payne, K, Zheng, B, Usas, A, Peng, H and Huard, J (2009). The dose of growth factors influences the synergistic effect of vascular endothelial growth factor on bone morphogenetic protein 4-induced ectopic bone formation. Tissue Eng Part A 15: 2123-2133.
23. Robbins, PD and Ghivizzani, SC (1998). Viral vectors for gene therapy. Pharmacol Ther 80: 35-47. (Pubitemid 28498200)
24. Evans, CH, Ghivizzani, SC and Robbins, PD (2004). The 2003 Nicolas Andry Award. Orthopaedic gene therapy. Clin Orthop Relat Res: 316-329. (Pubitemid 39579228)
25. Gazit, D, Turgeman, G, Kelley, P, Wang, E, Jalenak, M, Zilberman, Y et al. (1999). Engineered pluripotent mesenchymal cells integrate and differentiate in regenerating bone: a novel cell-mediated gene therapy. J Gene Med 1: 121-133. (Pubitemid 129631069)
26. Lieberman, JR, Le, LQ, Wu, L, Finerman, GA, Berk, A, Witte, ON et al. (1998). Regional gene therapy with a BMP-2-producing murine stromal cell line induces heterotopic and orthotopic bone formation in rodents. J Orthop Res 16: 330-339. (Pubitemid 28337629)
27. Krebsbach, PH, Gu, K, Franceschi, RT and Rutherford, RB (2000). Gene therapydirected osteogenesis: BMP-7-transduced human fibroblasts form bone in vivo. Hum Gene Ther 11: 1201-1210. (Pubitemid 30331585)
28. Betz, OB, Betz, VM, Abdulazim, A, Penzkofer, R, Schmitt, B, Schröder, C et al. (2009). Healing of large segmental bone defects induced by expedited bone morphogenetic protein-2 gene-activated, syngeneic muscle grafts. Hum Gene Ther 20: 1589-1596.
29. Baltzer, AW and Lieberman, JR (2004). Regional gene therapy to enhance bone repair. Gene Ther 11: 344-350. (Pubitemid 38263084)
30. Betz, OB, Betz, VM, Abdulazim, A, Penzkofer, R, Schmitt, B, Schröder, C et al. (2009). The Repair of Critical Size Bone Defects using Expedited, Autologous BMP-2 Gene Activated Fat Implants. Tissue Eng Part A (epub ahead of print).
31. Iyer, M, Wu, L, Carey, M, Wang, Y, Smallwood, A and Gambhir, SS (2001). Two-step transcriptional amplification as a method for imaging reporter gene expression using weak promoters. Proc Natl Acad Sci USA 98: 14595-14600. (Pubitemid 33121437)
32. Lieberman, JR, Daluiski, A and Einhorn, TA (2002). The role of growth factors in the repair of bone. Biology and clinical applications. J Bone Joint Surg Am 84-A: 1032-1044.
33. Peterson, B, Zhang, J, Iglesias, R, Kabo, M, Hedrick, M, Benhaim, P et al. (2005). Healing of critically sized femoral defects, using genetically modified mesenchymal stem cells from human adipose tissue. Tissue Eng 11: 120-129. (Pubitemid 40515180)
34. Hsu, WK, Sugiyama, O, Park, SH, Conduah, A, Feeley, BT, Liu, NQ et al. (2007). Lentiviral-mediated BMP-2 gene transfer enhances healing of segmental femoral defects in rats. Bone 40: 931-938. (Pubitemid 46386528)
35. Bonab, MM, Alimoghaddam, K, Talebian, F, Ghaffari, SH, Ghavamzadeh, A and Nikbin, B (2006). Aging of mesenchymal stem cell in vitro. BMC Cell Biol 7: 14.
36. Rubio, D, Garcia-Castro, J, Martín, MC, de la Fuente, R, Cigudosa, JC, Lloyd, AC et al. (2005). Spontaneous human adult stem cell transformation. Cancer Res 65: 3035-3039. (Pubitemid 40524580)
37. Izadpanah, R, Kaushal, D, Kriedt, C, Tsien, F, Patel, B, Dufour, J et al. (2008). Longterm in vitro expansion alters the biology of adult mesenchymal stem cells. Cancer Res 68: 4229-4238.
38. Evans, CH, Liu, FJ, Glatt, V, Hoyland, JA, Kirker-Head, C, Walsh, A et al. (2009). Use of genetically modified muscle and fat grafts to repair defects in bone and cartilage. Eur Cell Mater 18: 96-111.
39. Goldstein, SA (2000). In vivo nonviral delivery factors to enhance bone repair. Clin Orthop Relat Res (379 Suppl): S113-S119.
40. Iyer, M, Salazar, FB, Lewis, X, Zhang, L, Wu, L, Carey, M et al. (2005). Noninvasive imaging of a transgenic mouse model using a prostate-specific two-step transcriptional amplification strategy. Transgenic Res 14: 47-55. (Pubitemid 40374667)
41. Iyer, M, Salazar, FB, Lewis, X, Zhang, L, Carey, M, Wu, L et al. (2004). Noninvasive imaging of enhanced prostate-specific gene expression using a two-step transcriptional amplification-based lentivirus vector. Mol Ther 10: 545-552. (Pubitemid 39186115)
42. Connolly, JB (2002). Lentiviruses in gene therapy clinical research. Gene Ther 9: 1730-1734.
43. Sinn, PL, Sauter, SL and McCray, PB Jr (2005). Gene therapy progress and prospects: development of improved lentiviral and retroviral vectors-design, biosafety, and production. Gene Ther 12: 1089-1098. (Pubitemid 41030614)
44. Connolly, JF, Guse, R, Tiedeman, J and Dehne, R (1989). Autologous marrow injection for delayed unions of the tibia: a preliminary report. J Orthop Trauma 3: 276-282.
45. Hernigou, P, Poignard, A, Beaujean, F and Rouard, H (2005). Percutaneous autologous bone-marrow grafting for nonunions. Influence of the number and concentration of progenitor cells. J Bone Joint Surg Am 87: 1430-1437. (Pubitemid 40917741)
46. Cuomo, AV, Virk, M, Petrigliano, F, Morgan, EF and Lieberman, JR (2009). Mesenchymal stem cell concentration and bone repair: potential pitfalls from bench to bedside. J Bone Joint Surg Am 91: 1073-1083.
47. Stieger, K, Belbellaa, B, Le Guiner, C, Moullier, P and Rolling, F (2009). In vivo gene regulation using tetracycline-regulatable systems. Adv Drug Deliv Rev 61: 527-541.
48. Gamradt, SC, Abe, N, Bahamonde, ME, Lee, YP, Nelson, SD, Lyons, KM et al. (2006). Tracking expression of virally mediated BMP-2 in gene therapy for bone repair. Clin Orthop Relat Res 450: 238-245. (Pubitemid 44342141)
49. Sugiyama, O, An, DS, Kung, SP, Feeley, BT, Gamradt, S, Liu, NQ et al. (2005). Lentivirus-mediated gene transfer induces long-term transgene expression of BMP-2 in vitro and new bone formation in vivo. Mol Ther 11: 390-398. (Pubitemid 40277315)